JPH0898685A - New aspartic proteinase - Google Patents
New aspartic proteinaseInfo
- Publication number
- JPH0898685A JPH0898685A JP6261661A JP26166194A JPH0898685A JP H0898685 A JPH0898685 A JP H0898685A JP 6261661 A JP6261661 A JP 6261661A JP 26166194 A JP26166194 A JP 26166194A JP H0898685 A JPH0898685 A JP H0898685A
- Authority
- JP
- Japan
- Prior art keywords
- tyr
- aspartic proteinase
- enzyme
- gly
- rhizopus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004580 Aspartic Acid Proteases Human genes 0.000 title claims abstract description 46
- 108010017640 Aspartic Acid Proteases Proteins 0.000 title claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 240000005384 Rhizopus oryzae Species 0.000 claims abstract description 11
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims abstract description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims abstract description 5
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims abstract description 4
- 241000235527 Rhizopus Species 0.000 claims description 8
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 235000019833 protease Nutrition 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 28
- 108090000790 Enzymes Proteins 0.000 abstract description 28
- 229940088598 enzyme Drugs 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 23
- 239000005018 casein Substances 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 102000057297 Pepsin A Human genes 0.000 abstract description 4
- 108090000284 Pepsin A Proteins 0.000 abstract description 4
- 230000002378 acidificating effect Effects 0.000 abstract description 4
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 229940111202 pepsin Drugs 0.000 abstract description 4
- 102100029727 Enteropeptidase Human genes 0.000 abstract description 3
- 108010013369 Enteropeptidase Proteins 0.000 abstract description 3
- 239000013566 allergen Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000011194 food seasoning agent Nutrition 0.000 abstract description 3
- 239000004278 EU approved seasoning Substances 0.000 abstract description 2
- 102000038379 digestive enzymes Human genes 0.000 abstract description 2
- 108091007734 digestive enzymes Proteins 0.000 abstract description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 abstract 1
- 201000010859 Milk allergy Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000228212 Aspergillus Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000008192 Lactoglobulins Human genes 0.000 description 4
- 108010060630 Lactoglobulins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000018690 Trypsinogen Human genes 0.000 description 4
- 108010027252 Trypsinogen Proteins 0.000 description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 4
- 239000001639 calcium acetate Substances 0.000 description 4
- 235000011092 calcium acetate Nutrition 0.000 description 4
- 229960005147 calcium acetate Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000029534 trypsinogen activation Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000228251 Aspergillus phoenicis Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- XJRIDJAGAYGJCK-UHFFFAOYSA-N (1-acetyl-5-bromoindol-3-yl) acetate Chemical compound C1=C(Br)C=C2C(OC(=O)C)=CN(C(C)=O)C2=C1 XJRIDJAGAYGJCK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108700016171 Aspartate ammonia-lyases Proteins 0.000 description 1
- 108010055400 Aspartate kinase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010064711 Homoserine dehydrogenase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- MKAAKOISGFVECA-VQKCLUMFSA-N N-diazoacetylnorleucine methyl ester Chemical compound CCCC[C@@H](C(=O)OC)N\C([O-])=C\[N+]#N MKAAKOISGFVECA-VQKCLUMFSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、リゾプス・ハンショウ
(Rhizopus hangchow) が産生するアスパルチック・プ
ロティナーゼに関する。FIELD OF THE INVENTION The present invention relates to Rhizopus hansho.
( Rhizopus hangchow ) produced aspartic proteinase.
【0002】[0002]
【従来の技術】アスパルチック・プロティナーゼは、作
用至適pHが酸性側にあり活性部位にアスパラギン酸残基
を有するプロティナーゼの総称で、消化薬や麹の補助剤
あるいは代替品として用いられたり、調味液やペプチド
などを製造する際に用いられたりしている。このアスパ
ルチック・プロティナーゼの起源としては、動物の胃液
中のペプシンや仔牛胃のレンニンなどが広く知られてい
る。また、アスペルギルス(Aspergillus) 属、ペニシリ
ウム(Penicillium) 属、リゾプス(Rhizopus)属、ムコー
ル(Mucor) 属、サッカロミセス(Saccharomyces) 属など
の微生物もアスパルチック・プロティナーゼの起源とし
て知られている。BACKGROUND OF THE INVENTION Aspartic proteinase is a generic term for proteinases having an optimum pH for action on the acidic side and having an aspartic acid residue at the active site. It is used as an auxiliary agent or a substitute for digestive drugs and koji, and as a seasoning. It is also used when manufacturing liquids and peptides. As the origin of this aspartic proteinase, pepsin in animal gastric juice and rennin in calf stomach are widely known. Also, Aspergillus (Aspergillus) genus, penicillin <br/> um (Penicillium) genus, Rhizopus (Rhizopus) genus, Muko <br/> Le (Mucor) genus Saccharomyces (Saccharomyces) microorganisms such as genus also aspartokinase Chick proteinase Known as the origin.
【0003】[0003]
【発明が解決しようとする課題】本発明者らは、微生物
を起源とする種々の酵素について鋭意研究を行っていた
ところ、リゾプス・ハンショウ (Rhizopus hangchow)
がアスパルチック・プロティナーゼを産生することを見
出し、本発明をなすに至った。したがって、本発明は、
リゾプス・ハンショウ (Rhizopus hangchow) が産生す
るアスパルチック・プロティナーゼを提供することを課
題とする。DISCLOSURE OF INVENTION Problems to be Solved by the Invention The inventors of the present invention have conducted extensive research on various enzymes originating from microorganisms, and found that Rhizopus hangchow
Have been found to produce aspartic proteinase, and have completed the present invention. Therefore, the present invention
An object is to provide an aspartic proteinase produced by Rhizopus hangchow .
【0004】[0004]
【課題を解決するための手段】本発明は、アスパルチッ
ク・プロティナーゼ産生能を有するリゾプス・ハンショ
ウ (Rhizopus hangchow) を培養し、菌体中にアスパル
チック・プロティナーゼを生成、蓄積させた後、分離、
精製することにより得られるアスパルチック・プロティ
ナーゼであり、分子量約37,600(SDS-PAGE)を有し、次
のN末端アミノ酸配列を有する。 Ser-Gly-Ser-Gly-Val-Val-Phe-Met-Thr-Asp-Tyr-Glu-Ty
r-Asp-Ile-Glu-Tyr-Tyr-Gly-Means for Solving the Problems The present invention comprises culturing Rhizopus hangchow , which has an aspartic proteinase-producing ability, and producing and accumulating aspartic proteinase in cells, followed by separation,
It is an aspartic proteinase obtained by purification, has a molecular weight of about 37,600 (SDS-PAGE), and has the following N-terminal amino acid sequence. Ser-Gly-Ser-Gly-Val-Val-Phe-Met-Thr-Asp-Tyr-Glu-Ty
r-Asp-Ile-Glu-Tyr-Tyr-Gly-
【0005】次に、本発明のアスパルチック・プロティ
ナーゼの製造法について説明する。本発明のアスパルチ
ック・プロティナーゼの製造に用いるリゾプス・ハンシ
ョウ (Rhizopus hangchow) は、本発明のアスパルチッ
ク・プロティナーゼを産生するものであればいずれの菌
株でも良く、例えばその菌株として、リゾプス・ハンシ
ョウ (Rhizopus hangchow) IFO-4749株を挙げることが
できる。このIFO-4749株は財団法人発酵研究所(Institu
te for Fermentation, Osaka) で何らの制限を受けるこ
と無く入手することができる。Next, a method for producing the aspartic proteinase of the present invention will be described. Rhizopus disprove used in the production of aspartate Chick proteinase of the present invention (Rhizopus hangchow), as long as it produces aspartase tic proteinase of the present invention may be any strain, such as a strain, Rhizopus disproved (Rhizopus hangchow ) IFO-4749 strain. This IFO-4749 strain is a fermentation research institute (Institu
te for Fermentation, Osaka) can be obtained without any restrictions.
【0006】本発明のアスパルチック・プロティナーゼ
を製造する際に行うリゾプス・ハンショウ (Rhizopus
hangchow) の培養に用いる培地は、通常のリゾプス・ハ
ンショウ (Rhizopus hangchow) の培養に用いる培地で
あれば良く、液体培地を用いることもできるし、固体培
地を用いることもできる。また、本発明のアスパルチッ
ク・プロティナーゼを産生させるための誘導物質は特に
必要としない。なお、培養温度は25℃前後が好ましく、
培養時間は4日程度で良い。[0006] Rhizopus hansho ( Rhizopus) used in the production of the aspartic proteinase of the present invention
The medium used for culturing hangchow ) may be any medium used for culturing ordinary Rhizopus hangchow , and may be a liquid medium or a solid medium. Moreover, an inducer for producing the aspartic proteinase of the present invention is not particularly required. The culture temperature is preferably around 25 ° C,
The culture time may be about 4 days.
【0007】このようにリゾプス・ハンショウ (Rhizop
us hangchow) の菌体中に生成、蓄積させたアスパルチ
ック・プロティナーゼの精製は、酵素の精製に通常用い
られる方法を適宜組み合わせることにより行われる。例
えば、液体培養においては、濾過や遠心分離などの処理
により培養物から菌体を分離した後、酵素処理や物理的
処理により菌体を破砕し、アスパルチック・プロティナ
ーゼを溶出させて粗酵素画分を得る。また、固体培養に
おいては、緩衝液などの溶媒を用いてアスパルチック・
プロティナーゼの粗酵素画分を抽出する。そして、この
粗酵素画分は、硫安分画、イオン交換クロマトグラフィ
ー、ゲル濾過クロマトグラフィーなどの処理により精製
される。[0007] Thus, Rhizop
purification of the aspartic proteinase produced and accumulated in the cells of Us hangchow ) is carried out by appropriately combining the methods usually used for the purification of the enzyme. For example, in liquid culture, cells are separated from the culture by treatment such as filtration or centrifugation, and then the cells are crushed by enzymatic or physical treatment, and aspartic proteinase is eluted to obtain a crude enzyme fraction. To get In solid-state culture, a solvent such as a buffer may be used to
The crude enzyme fraction of proteinase is extracted. Then, the crude enzyme fraction is purified by a treatment such as ammonium sulfate fractionation, ion exchange chromatography, gel filtration chromatography and the like.
【0008】次に、本発明のアスパルチック・プロティ
ナーゼの理化学的性質を示す。 (1) 分子量:SDS-PAGEで37,600であり、Superoseを用い
たファースト・プロテイン・リキッド・クロマトグラフ
(FPLC)で36,000である。 (2) 等電点:等電点電気泳動で 4.5である。 (3) 基質特異性:インシュリンB鎖中の Leu15-Tyr16及
び Tyr16-Leu17の二つのペプチド結合を初期に切断し、
さらに、 Leu11-Val12、 Ala14-Leu15及び Phe24-Phe25
を切断する。また、トリプシノーゲンをpH2〜5の領域
で活性化する。 (4) 至適pH:pH3〜4である(図1参照)。 (5) 熱安定性:pH 3.0で45℃、5分間の処理により酵素
活性は減少し、pH 3.0で50℃、5分間の処理により酵素
活性は完全に消失する。 (6) pH安定性:pH2〜7で極めて安定である(図2参
照)。また、pH 9.0で、5℃、一夜の処理により酵素活
性の約50%が減少する。 (7) 阻害剤:1μM のペプスタチンAにより酵素活性は
完全に消失し、14℃、40分間のN-ジアゾアセチルノルロ
イシンメチル エステル(N-diazoacetylnorleucinemeth
yl ester)(DAN)処理により酵素活性の約56%が減少す
る。 (8) N末端アミノ酸配列:Ser-Gly-Ser-Gly-Val-Val-Ph
e-Met-Thr-Asp-Tyr-Glu-Tyr-Asp-Ile-Glu-Tyr-Tyr-Gly- (9) 構造:円偏光二色性スペクトルの測定(図3参照)
により、約90%のβ−構造を有する。Next, the physicochemical properties of the aspartic proteinase of the present invention will be shown. (1) Molecular weight: 37,600 by SDS-PAGE, fast protein liquid chromatograph using Superose
(FPLC) is 36,000. (2) Isoelectric point: It is 4.5 by isoelectric focusing. (3) Substrate specificity: two peptide bonds of Leu 15 -Tyr 16 and Tyr 16 -Leu 17 in the insulin B chain are cleaved initially,
In addition, Leu 11 -Val 12 , Ala 14 -Leu 15 and Phe 24 -Phe 25
Disconnect. It also activates trypsinogen in the pH range of 2-5. (4) Optimum pH: pH 3 to 4 (see FIG. 1). (5) Thermostability: Treatment at 45 ° C for 5 minutes at pH 3.0 reduces enzyme activity, and treatment at 50 ° C for 5 minutes at pH 3.0 completely eliminates enzyme activity. (6) pH stability: It is extremely stable at pH 2 to 7 (see FIG. 2). In addition, about 50% of enzyme activity is reduced by overnight treatment at pH 9.0 at 5 ° C. (7) Inhibitor: The enzyme activity was completely eliminated by 1 μM of pepstatin A, and N-diazoacetylnorleucine methyl ester (N-diazoacetylnorleucinemethase) was incubated at 14 ° C for 40 minutes.
yl ester) (DAN) treatment reduces approximately 56% of enzyme activity. (8) N-terminal amino acid sequence: Ser-Gly-Ser-Gly-Val-Val-Ph
e-Met-Thr-Asp-Tyr-Glu-Tyr-Asp-Ile-Glu-Tyr-Tyr-Gly- (9) Structure: Circular dichroism spectrum measurement (see Figure 3)
Has about 90% β-structure.
【0009】なお、アスパルチック・プロティナーゼ活
性は、以下のようにして測定した。0.1Mクエン酸緩衝液
(pH 3.0)で希釈した酵素液1mlに2%ミルクカゼイン溶
液1mlを加え、30℃で10分間反応させた。0.4Mトリクロ
ロ酢酸2mlを加えて反応を停止させた後、20分間以上放
置し、トーヨー濾紙 NO.2 で濾過した。この濾液1mlに
0.4M炭酸ナトリウム5mlを加えて充分撹拌した後、6倍
希釈 Folin-Ciocalteu試薬1mlを加えて30℃で30分間放
置し、吸光度 660nmを測定した。これとは別に予め失活
させておいた酵素液を用い盲検を行った。酵素活性は、
30℃、pH 3.0で2%ミルクカゼイン水溶液を基質として
酵素反応を行った際に、1秒間にチロシン1mole相当の
280nmの吸光度と同等のトリクロロ酢酸可溶性分解物を
遊離させる酵素量を1katal とした。また、酵素蛋白質
1kg当たりの katal数で比活性を示した。The aspartic proteinase activity was measured as follows. 0.1M citrate buffer
1 ml of a 2% milk casein solution was added to 1 ml of the enzyme solution diluted with (pH 3.0) and reacted at 30 ° C. for 10 minutes. After the reaction was stopped by adding 2 ml of 0.4 M trichloroacetic acid, the mixture was allowed to stand for 20 minutes or longer, and filtered with Toyo filter paper No.2. To 1 ml of this filtrate
After adding 5 ml of 0.4 M sodium carbonate and thoroughly stirring, 1 ml of a 6-fold diluted Folin-Ciocalteu reagent was added and the mixture was allowed to stand at 30 ° C. for 30 minutes to measure the absorbance at 660 nm. Separately from this, a blind test was performed using an enzyme solution that had been inactivated in advance. The enzyme activity is
When an enzyme reaction was performed using a 2% milk casein aqueous solution as a substrate at 30 ° C and pH 3.0, 1 mole of tyrosine equivalent to 1 second was obtained.
The amount of enzyme that liberates a trichloroacetic acid-soluble degradation product equivalent to the absorbance at 280 nm was set to 1 katal. Moreover, the specific activity was shown by the number of katal per 1 kg of enzyme protein.
【0010】以下、実施例により、本発明をさらに詳細
に説明する。Hereinafter, the present invention will be described in more detail with reference to examples.
【実施例1】粗酵素の調製 小麦ふすま1,800gに水 1,500mlを加えて殺菌した後、リ
ゾプス・ハンショウ (Rhizopus hangchow) IFO-4749株
を接種し、25℃で4日間培養した。培養後、得られた麹
に20mMリン酸緩衝液(pH7.0) 10,000mlを加え、低温室に
て一夜抽出を行い、粗酵素液 7,350mlを得た。この粗酵
素液を遠心分離した後、ホローファイバー(AIL-1010、
旭化成社製) を用いて濃縮し、凍結乾燥して粗酵素粉末
15.5gを得た。このアスパルチック・プロティナーゼ粗
酵素粉末の比活性は 7.9×10-3katal/kg蛋白質であっ
た。また、アスパルチック・プロティナーゼ活性の収率
は68%であった。Example 1 Preparation of crude enzyme To 1,800 g of wheat bran was added 1,500 ml of water for sterilization, and then Rhizopus hangchow IFO-4749 strain was inoculated and cultured at 25 ° C. for 4 days. After culturing, 10,000 ml of 20 mM phosphate buffer (pH 7.0) was added to the obtained koji, and the mixture was extracted overnight in a low temperature room to obtain 7,350 ml of a crude enzyme solution. After centrifuging this crude enzyme solution, hollow fiber (AIL-1010,
Asahi Kasei Co., Ltd.), and freeze-dried to obtain crude enzyme powder.
15.5 g was obtained. The specific activity of this crude aspartic proteinase enzyme powder was 7.9 × 10 −3 katal / kg protein. The yield of aspartic proteinase activity was 68%.
【0011】アスパルチック・プロティナーゼの精製 上記のようにして得られた粗酵素粉末 10gを2mM酢酸カ
ルシウム含有10mMクエン酸緩衝液(pH 5.2) 100mlに懸濁
し、2時間撹拌して溶解した後、遠心分離 (15,000×
g、20分) し、得られた上清を同緩衝液に対して透析し
た。透析後、遠心分離 (15,000×g、20分) し、その上
清を粗酵素液とした。この上清に35%濃度となるよう硫
安を穏やかに加え、遠心分離 (10,000×g、20分) し、
その上清を35%硫安画分上清とした。比活性は 8.7×10
-3katal/kg蛋白質であった。 Purification of aspartic proteinase 10 g of the crude enzyme powder obtained as described above was suspended in 100 ml of 10 mM citrate buffer (pH 5.2) containing 2 mM calcium acetate, stirred for 2 hours to dissolve, and then centrifuged. Separation (15,000 ×
g, 20 minutes), and the resulting supernatant was dialyzed against the same buffer. After dialysis, centrifugation (15,000 xg, 20 minutes) was performed, and the supernatant was used as a crude enzyme solution. Ammonium sulfate was gently added to this supernatant to a concentration of 35%, centrifuged (10,000 xg, 20 minutes),
The supernatant was used as a 35% ammonium sulfate fraction supernatant. Specific activity 8.7 × 10
It was -3 katal / kg protein.
【0012】この35%硫安画分上清を予め35%硫安濃度
の2mM酢酸カルシウム含有10mMクエン酸緩衝液(pH 5.2)
で平衡化したButyl-TOYOPEARL 650M (東ソー株式会社
製) に供した。そして、35〜0%硫安濃度直線濃度勾配
により活性画分を溶出し、その溶出液をButyl-TOYOPEAR
L 650M溶出活性画分とした。比活性は 9.1×10-3katal/
kg蛋白質であった。The supernatant of this 35% ammonium sulfate fraction was preliminarily used as a 10 mM citrate buffer (pH 5.2) containing 35 mM ammonium sulfate at a concentration of 2 mM calcium acetate.
It was used for Butyl-TOYOPEARL 650M (manufactured by Tosoh Corporation) equilibrated with. Then, the active fraction was eluted with a linear concentration gradient of 35 to 0% ammonium sulfate, and the eluate was diluted with Butyl-TOYOPEAR.
It was used as an L 650M elution active fraction. Specific activity is 9.1 × 10 -3 katal /
It was kg protein.
【0013】このButyl-TOYOPEARL 650M溶出活性画分を
2mM酢酸カルシウム含有10mMクエン酸緩衝液(pH 5.0)に
対して充分透析した後、同緩衝液で平衡化したDEAE-TOY
OPEARL 650S(東ソー株式会社製) に供した。そして、0
〜0.5M塩化ナトリウム直線濃度勾配により活性画分を溶
出し、その溶出液をDEAE-TOYOPEARL 650S 溶出活性画分
とした。比活性は15.8×10-3katal/kg蛋白質であった。This Butyl-TOYOPEARL 650M elution active fraction was thoroughly dialyzed against 10 mM citrate buffer (pH 5.0) containing 2 mM calcium acetate, and then DEAE-TOY equilibrated with the same buffer.
It was used for OPEARL 650S (manufactured by Tosoh Corporation). And 0
The active fraction was eluted with a linear gradient of ~ 0.5 M sodium chloride, and the eluate was used as the DEAE-TOYOPEARL 650S eluting active fraction. The specific activity was 15.8 × 10 -3 katal / kg protein.
【0014】このDEAE-TOYOPEARL 650S 溶出活性画分を
2mM酢酸カルシウム含有10mMクエン酸緩衝液(pH 3.0)に
対して十分透析した後、同緩衝液で平衡化したSP-TOYOP
EARL650M(東ソー株式会社製) に供した。そして、0〜
0.75M 塩化ナトリウム直線濃度勾配により活性画分を溶
出し、その溶出液をSP-TOYOPEARL 650M 溶出活性画分と
した。The DEAE-TOYOPEARL 650S elution active fraction was thoroughly dialyzed against 10 mM citrate buffer (pH 3.0) containing 2 mM calcium acetate, and then equilibrated with SP-TOYOP.
It was used for EARL650M (manufactured by Tosoh Corporation). And 0-
The active fraction was eluted with a linear gradient of 0.75M sodium chloride, and the eluate was designated as SP-TOYOPEARL 650M eluting active fraction.
【0015】このSP-TOYOPEARL 650M 溶出活性画分をミ
リQ水に対して十分透析し、凍結乾燥して精製アスパル
チック・プロティナーゼ 212mgを得た。このようにして
得られた精製アスパルチック・プロティナーゼは、電気
泳動的に単一であり、比活性は11×10-3katal/kg蛋白質
であった。また、アスパルチック・プロティナーゼ活性
の収率は8%であった。This SP-TOYOPEARL 650M elution active fraction was thoroughly dialyzed against Milli-Q water and freeze-dried to obtain 212 mg of purified aspartic proteinase. The purified aspartic proteinase thus obtained was electrophoretically single and had a specific activity of 11 × 10 −3 katal / kg protein. The yield of aspartic proteinase activity was 8%.
【0016】[0016]
【試験例1】実施例1で得られたアスパルチック・プロ
ティナーゼのトリプシノーゲン活性化反応を調べた。
2.5mM塩酸に0.5mg/ml濃度となるようトリプシノーゲン
を溶解した溶液25μl 、10mMクエン酸ナトリウム緩衝液
(pH 3.0)50μl 、酵素液25μlを混合し、30℃で活性化
反応を行った後、0.3Mトリス−塩酸緩衝液(pH 8.3) 0.5
ml、水 0.9mlを加えて反応を停止した。そして、この溶
液に10mM Bz-Arg-MCA 5μl を加えて30℃で反応させた
後、Fluorescence Spectrophotometer F-3000(株式会社
日立製作所製) を用いて励起波長 360nm、蛍光波長 440
nmにて蛍光強度を測定した。この条件において、1秒間
にトリプシノーゲン1moleを活性化するのに必要な酵素
量を1katal とした。その結果、本発明のアスパルチッ
ク・プロティナーゼのトリプシノーゲン活性化反応にお
ける比活性は13.9×10-3katal/kg蛋白質であった。TEST EXAMPLE 1 The trypsinogen activation reaction of the aspartic proteinase obtained in Example 1 was examined.
25 μl of a solution of trypsinogen dissolved in 2.5 mM hydrochloric acid to a concentration of 0.5 mg / ml, 10 mM sodium citrate buffer
(pH 3.0) 50 μl and enzyme solution 25 μl were mixed, and after activation reaction at 30 ° C., 0.3 M Tris-HCl buffer (pH 8.3) 0.5
The reaction was stopped by adding ml and 0.9 ml of water. Then, 10 μM Bz-Arg-MCA (5 μl) was added to this solution and reacted at 30 ° C., and then using a Fluorescence Spectrophotometer F-3000 (manufactured by Hitachi, Ltd.), an excitation wavelength of 360 nm and a fluorescence wavelength of 440
The fluorescence intensity was measured at nm. Under these conditions, the amount of enzyme required to activate 1 mole of trypsinogen per second was 1 katal. As a result, the specific activity of the aspartic proteinase of the present invention in the trypsinogen activation reaction was 13.9 × 10 −3 katal / kg protein.
【0017】[0017]
【試験例2】実施例1で得られたアスパルチック・プロ
ティナーゼのアレルゲン蛋白質に対する分解能を調べ
た。2%αS −カゼイン(pH 3.0)5μl 及び2%β−ラ
クトグロブリン(pH 3.0)5μl を基質とし、酵素溶液(p
H 3.0)5μl をそれぞれ加え30℃で反応させた後、0.8M
トリクロロ酢酸5μl を加えることにより反応を停止さ
せた。この反応液を30℃で20分間以上放置した後、遠心
分離 (15,000×g、20分) して沈澱物を得た。そして、
この沈澱物を SDS化した後、SDS-PAGEに供して分解の様
子を見た。その結果を図4に示す。本発明のアスパルチ
ック・プロティナーゼは、αS −カゼインは分解する
が、β−ラクトグロブリンは分解しないことが判った。TEST EXAMPLE 2 The ability of the aspartic proteinase obtained in Example 1 for the allergen protein was examined. Using 5 μl of 2% α S -casein (pH 3.0) and 5 μl of 2% β-lactoglobulin (pH 3.0) as a substrate, the enzyme solution (p
H 3.0) 5 μl was added to each well and reacted at 30 ° C, then 0.8M
The reaction was stopped by adding 5 μl of trichloroacetic acid. The reaction solution was allowed to stand at 30 ° C. for 20 minutes or longer and then centrifuged (15,000 × g, 20 minutes) to obtain a precipitate. And
After converting this precipitate into SDS, it was subjected to SDS-PAGE to observe the state of decomposition. The result is shown in FIG. It was found that the aspartic proteinase of the present invention decomposes α S -casein but not β-lactoglobulin.
【0018】[0018]
【試験例3】実施例1で得られたアスパルチック・プロ
ティナーゼの酸化インシュリンB鎖に対する基質特異性
を調べた。酸化インシュリンB鎖 (シグマ社製) を HPL
C TSK-gel ODS-120Tに供して精製したものを基質として
用い、30℃、pH 3.0で酵素反応を行った。25%アンモニ
ア水を1/10量加えることによって反応を停止した後、減
圧乾固し 0.1%TFA に溶解して試料とした。この試料を
HPLC TSK-gel ODS-120Tに供してピークを分取し、各ピ
ークのアミノ酸配列をペプチドシークェンサー(Applied
Biosystems 477A Protein sequencer;アプライド・バ
イオシステムズ社製) で分析して、切断点及び切断の順
序を決定した。本発明のアスパルチック・プロティナー
ゼは、 Leu15-Tyr16及び Tyr16-Leu17の二つのペプチド
結合を初期に切断し、さらに、 Leu11-Val12、 Ala14-L
eu15及び Phe24-Phe25を切断することが判った。[Test Example 3] The substrate specificity of the aspartic proteinase obtained in Example 1 for the oxidized insulin B chain was examined. HPL of oxidized insulin B chain (manufactured by Sigma)
An enzyme reaction was carried out at 30 ° C. and pH 3.0 using the substrate purified by C TSK-gel ODS-120T. The reaction was stopped by adding 1/10 volume of 25% aqueous ammonia, dried under reduced pressure, dissolved in 0.1% TFA, and used as a sample. This sample
Peaks were collected by HPLC TSK-gel ODS-120T, and the amino acid sequence of each peak was analyzed by peptide sequencer (Applied
Biosystems 477A Protein sequencer (manufactured by Applied Biosystems) was used to determine the cutting points and the cutting order. The aspartic proteinase of the present invention initially cleaves two peptide bonds of Leu 15 -Tyr 16 and Tyr 16 -Leu 17 , and further, Leu 11 -Val 12 , Ala 14 -L.
It was found to cleave eu 15 and Phe 24 -Phe 25 .
【0019】[0019]
【試験例4】実施例1で得られたアスパルチック・プロ
ティナーゼの凝乳活性を調べた。1レーン当たり 0.1μ
g 、 0.5μg 、 1.0μg となるよう酵素を供し、15V/cm
で2時間、アガロース電気泳動を行った。泳動後、ゲル
を 0.15M酢酸緩衝液(pH 5.3)に浸漬し、30分間、室温に
放置した後、スキムミルク−アガロースプレートに載せ
た。37℃で2時間反応させた後、0.02% amido blackを
加えて20分間染色し、水洗した後、5% glycerol を含
む 0.01M酢酸緩衝液(pH 5.8)で脱色した。また、比較例
として、アスペルギルス・サイトイ(Aspergillus sait
oi) 由来のアスパルチック・プロティナーゼについても
同様の試験を行った。その結果を図5に示す。本発明の
アスパルチック・プロティナーゼは、アスペルギルス・
サイトイ(Aspergillus saitoi) 由来のアスパルチック
・プロティナーゼよりも強い凝乳活性を有することが判
った。TEST EXAMPLE 4 The coagulant activity of the aspartic proteinase obtained in Example 1 was examined. 0.1μ per lane
15V / cm, using enzyme to give g, 0.5 μg, 1.0 μg
Electrophoresis was carried out for 2 hours. After the electrophoresis, the gel was immersed in 0.15 M acetate buffer (pH 5.3), allowed to stand at room temperature for 30 minutes, and then placed on a skim milk-agarose plate. After reacting at 37 ° C. for 2 hours, 0.02% amido black was added, stained for 20 minutes, washed with water, and then decolorized with 0.01 M acetate buffer (pH 5.8) containing 5% glycerol. As a comparative example, Aspergillus sait
The same test was carried out on the aspartic proteinase derived from ( oi ). The result is shown in FIG. The aspartic proteinase of the present invention comprises Aspergillus
It was found to have stronger milk-clotting activity than the aspartic proteinase from Cytoi (Aspergillus saitoi ).
【0020】[0020]
【発明の効果】本発明のアスパルチック・プロティナー
ゼは、pH2〜7で安定であり、酸性領域で蛋白質を良好
に分解することから、胃液で分泌されるペプシンの代替
品として有用であると共に、pH3〜4で膵臓由来のトリ
プシノーゲンを活性化することから、十二指腸で分泌さ
れるエンテロキナーゼの代替品としても有用である。ま
た、本発明のアスパルチック・プロティナーゼは、ペプ
シンとエンテロキナーゼの二つの機能を有する消化酵素
であり、αS −カゼインの分解能を有するので、消化管
が未成熟な新生児のための消化剤として用いることによ
り、新生児にとって問題となる乳や卵などのアレルギー
を予防することが可能となる。さらに、本発明のアスパ
ルチック・プロティナーゼは、雑菌に汚染され難い酸性
領域で高い活性を示すので、調味料や低アレルゲン化食
品などの食品素材を製造する際に用いる蛋白質分解酵素
としても最適である。INDUSTRIAL APPLICABILITY The aspartic proteinase of the present invention is stable at pH 2 to 7 and decomposes proteins well in the acidic region. Therefore, it is useful as a substitute for pepsin secreted in gastric juice and at pH 3 It activates pancreatic-derived trypsinogen at -4, and thus is also useful as a substitute for enterokinase secreted in the duodenum. Further, the aspartic proteinase of the present invention is a digestive enzyme having two functions of pepsin and enterokinase, and since it has the ability to decompose α S -casein, it is used as a digestive agent for neonates with immature gastrointestinal tract. As a result, it becomes possible to prevent allergies such as milk and eggs, which are a problem for newborns. Furthermore, since the aspartic proteinase of the present invention exhibits high activity in an acidic region that is unlikely to be contaminated by various bacteria, it is also most suitable as a proteolytic enzyme used when producing food materials such as seasonings and hypoallergenic foods. .
【図1】本発明のアスパルチック・プロティナーゼのト
リプシノーゲン活性化に対するpHの影響を示す。FIG. 1 shows the effect of pH on trypsinogen activation of the aspartic proteinases of the present invention.
【図2】本発明のアスパルチック・プロティナーゼのト
リプシノーゲン活性化に対するpHの安定性を示す。FIG. 2 shows the pH stability of the aspartic proteinases of the present invention against trypsinogen activation.
【図3】本発明のアスパルチック・プロティナーゼの円
偏光二色性スペクトルの測定結果を示す。FIG. 3 shows the measurement results of the circular dichroism spectrum of the aspartic proteinase of the present invention.
【図4】本発明のアスパルチック・プロティナーゼによ
るアレルゲン蛋白質(αs −カゼイン、β−ラクトグロ
ブリン)の加水分解を示す。FIG. 4 shows hydrolysis of allergen proteins (α s -casein, β-lactoglobulin) by the aspartic proteinase of the present invention.
L-L 1 , 6 :マーカー蛋白質 L-L 2 , 3 , 4 :αs −カゼイン L-L 7 , 8 , 9 ,10 :β−ラクトグロブリンLL 1, 6: marker proteins LL 2, 3, 4: α s - casein LL 7, 8, 9, 10 : β- lactoglobulin
【図5】本発明のアスパルチック・プロティナーゼ及び
アスペルギルス・サイトイ(Aspergillus Saitoi) から
得られるアスパルチック・プロティナーゼの凝乳活性を
示す。FIG. 5 shows the milk- clotting activity of the aspartic proteinases and aspartic proteinases obtained from Aspergillus Saitoi of the present invention.
L-L 1 , 2 , 3 :本発明のアスパルチック・プロティナ
ーゼの凝乳活性 L-L 4 , 5 , 6 :アスペルギルス・サイトイのアスパル
チック・プロティナーゼの凝乳活性LL 1, 2, 3: Cottling activity of the aspartic proteinase of the present invention LL 4, 5, 6: Cottling activity of the aspartic proteinase of Aspergillus cytoii
フロントページの続き (72)発明者 宿野部 幸孝 埼玉県川越市古谷上6883−8 B2−205 (72)発明者 平野 賢一 愛知県岩倉市稲荷町稲荷西212番地11 (72)発明者 伊藤 浩史 愛知県岩倉市稲荷町221番地Front Page Continuation (72) Inventor Yukitaka Innobe 6883-8 Furuyaue, Kawagoe City, Saitama B2-205 (72) Inventor Kenichi Hirano 212 Inari Nishi, Inari Town, Iwakura City, Aichi Prefecture 11 (72) Inventor Hiroshi Ito Aichi 221 Inaricho, Iwakura City, Japan
Claims (2)
chow) が産生し、分子量約37,600(SDS-PAGE)を有し、
次のN末端アミノ酸配列を有するアスパルチック・プロ
ティナーゼ。 Ser-Gly-Ser-Gly-Val-Val-Phe-Met-Thr-Asp-Tyr-Glu-Ty
r-Asp-Ile-Glu-Tyr-Tyr-Gly-1. Rhizopus hang
chow ) has a molecular weight of about 37,600 (SDS-PAGE),
An aspartic proteinase having the following N-terminal amino acid sequence: Ser-Gly-Ser-Gly-Val-Val-Phe-Met-Thr-Asp-Tyr-Glu-Ty
r-Asp-Ile-Glu-Tyr-Tyr-Gly-
chow) が、リゾプス・ハンショウ (Rhizopus hangcho
w) IFO-4749株である請求項1記載のアスパルチック・
プロティナーゼ。2. Rhizopus hang
chow ), but Rhizopus hangcho
w ) The aspartic protein according to claim 1, which is the IFO-4749 strain.
Proteinase.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26166194A JP3547021B2 (en) | 1994-09-30 | 1994-09-30 | New aspartic proteinase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26166194A JP3547021B2 (en) | 1994-09-30 | 1994-09-30 | New aspartic proteinase |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0898685A true JPH0898685A (en) | 1996-04-16 |
JP3547021B2 JP3547021B2 (en) | 2004-07-28 |
Family
ID=17365009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP26166194A Expired - Fee Related JP3547021B2 (en) | 1994-09-30 | 1994-09-30 | New aspartic proteinase |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3547021B2 (en) |
-
1994
- 1994-09-30 JP JP26166194A patent/JP3547021B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3547021B2 (en) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ebeling et al. | Proteinase K from Tritirachium album limber | |
US5270176A (en) | Method for the selective cleavage of fusion proteins with lysostaphin | |
KR20000070231A (en) | Method for the selective degradation of milk protein in the presence of other milk proteins | |
Demir et al. | Cysteine protease (capparin) from capsules of caper (Capparis spinosa) | |
WO2002068671A1 (en) | Method of deamidation of milk protein and method of denaturation of milk protein | |
Oda et al. | Purification and properties of a proteinaceous metallo-proteinase inhibitor from Streptomyces nigrescens TK-23 | |
JPH02504465A (en) | Improvements in the isolation of active enzymes from krill tissue | |
JPH07115969A (en) | Production of hydrolyzed protein | |
AU618035B2 (en) | A method for the selective cleavage of fusion proteins | |
US4035234A (en) | Process for the preparation of the kallikrein-trypsin inhibitor | |
JPH0898685A (en) | New aspartic proteinase | |
JP7008767B2 (en) | Cold acidic protease PsAPA and its preparation method and application | |
JP3518868B2 (en) | Method for producing aminopeptidase and natural protein derived from Bacillus licheniformis strain | |
JP3364551B2 (en) | Method for producing low allergenic milk protein | |
Chauvet et al. | ISOLATION OF A TRYPSIN‐LIKE ENZYME FROM. STREPTOMYCES PAROMOMYCINUS (PAROMOTRYPSIN) BY AFFINITY ADSORPTION THROUGH KUNITZ INHIBITOR‐SEPHAROSE | |
Oza | β‐lytic protease, a neutral sorangiopeptidase | |
US4916062A (en) | Enzyme, its method of production and its application to the preparation of methyl N-(L-aspartyl-1) L-phenylalaninate | |
JPH07274995A (en) | Production of peptide | |
JP2643264B2 (en) | New thermostable alkaline protease and its manufacturing method | |
JPH06261691A (en) | Production of low allergenic milk protein | |
JPS60164496A (en) | Preparation of low-molecular peptide | |
JPS6156997B2 (en) | ||
JP2794371B2 (en) | Alkaline protease K-16H | |
JP3070975B2 (en) | New neutral protease and its production method | |
JP2000078971A (en) | New enzyme for synthesizing oligopeptide from d- or l- aminoacid ester and microorganism producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040408 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040408 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |